These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 22205688)

  • 1. Increasing potential of HER3 signaling in colon cancer progression and therapy.
    Gespach C
    Clin Cancer Res; 2012 Feb; 18(4):917-9. PubMed ID: 22205688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toward the prognostic significance and therapeutic potential of HER3 receptor tyrosine kinase in human colon cancer.
    Beji A; Horst D; Engel J; Kirchner T; Ullrich A
    Clin Cancer Res; 2012 Feb; 18(4):956-68. PubMed ID: 22142822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The HER3/ErbB3 receptor: a promising target in cancer drug therapy.
    Desbois-Mouthon C
    Gastroenterol Clin Biol; 2010; 34(4-5):255-9. PubMed ID: 20418034
    [No Abstract]   [Full Text] [Related]  

  • 4. Update on HER-kinase-directed therapy in prostate cancer.
    Gross ME; Jo S; Agus DB
    Clin Adv Hematol Oncol; 2004 Jan; 2(1):53-6, 64. PubMed ID: 16163160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The HER3/ERBB3 receptor: the dark side of the ERBB planet].
    Larbouret C; Gaborit N; Poul MA; Pèlegrin A; Chardès T
    Med Sci (Paris); 2015 May; 31(5):465-8. PubMed ID: 26059291
    [No Abstract]   [Full Text] [Related]  

  • 6. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
    Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
    Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
    Kim J; Lee J; Kim C; Choi J; Kim A
    Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
    Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
    Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
    Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
    Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological inhibition of p38 MAPK reduces tumor growth in patient-derived xenografts from colon tumors.
    Gupta J; Igea A; Papaioannou M; Lopez-Casas PP; Llonch E; Hidalgo M; Gorgoulis VG; Nebreda AR
    Oncotarget; 2015 Apr; 6(11):8539-51. PubMed ID: 25890501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER3 expression is correlated to distally located and low-grade colon cancer.
    Lédel F; Stenstedt K; Hallström M; Ragnhammar P; Edler D
    Acta Oncol; 2016 Jul; 55(7):875-80. PubMed ID: 26863446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gefitinib-responsive EGFR-positive colorectal cancers have different proteome profiles from non-responsive cell lines.
    Loeffler-Ragg J; Skvortsov S; Sarg B; Skvortsova I; Witsch-Baumgartner M; Mueller D; Lindner H; Zwierzina H
    Eur J Cancer; 2005 Oct; 41(15):2338-46. PubMed ID: 16115757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
    Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
    Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of cyclooxygenase-2 pathway by HER2 receptor.
    Vadlamudi R; Mandal M; Adam L; Steinbach G; Mendelsohn J; Kumar R
    Oncogene; 1999 Jan; 18(2):305-14. PubMed ID: 9927187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel agents and targets for the therapy of advanced colon cancer.
    Hoff PM
    Clin Adv Hematol Oncol; 2007 May; 5(5):365-6. PubMed ID: 17673891
    [No Abstract]   [Full Text] [Related]  

  • 16. Anti-epidermal growth factor receptor strategies for advanced breast cancer.
    Campos SM
    Cancer Invest; 2008 Oct; 26(8):757-68. PubMed ID: 18853311
    [No Abstract]   [Full Text] [Related]  

  • 17. Novel Peptidomimetics for Inhibition of HER2:HER3 Heterodimerization in HER2-Positive Breast Cancer.
    Kanthala S; Banappagari S; Gokhale A; Liu YY; Xin G; Zhao Y; Jois S
    Chem Biol Drug Des; 2015 Jun; 85(6):702-714. PubMed ID: 25346057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deficient HER3 expression in poorly-differentiated colorectal cancer cells enhances gefitinib sensitivity.
    Nakata S; Tanaka H; Ito Y; Hara M; Fujita M; Kondo E; Kanemitsu Y; Yatabe Y; Nakanishi H
    Int J Oncol; 2014 Oct; 45(4):1583-93. PubMed ID: 25017791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of HER3 in gastric cancer.
    Wang L; Yuan H; Li Y; Han Y
    Biomed Pharmacother; 2014 Jul; 68(6):809-12. PubMed ID: 25194439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies.
    Monteiro Ide P; Madureira P; de Vasconscelos A; Pozza DH; de Mello RA
    Pharmacogenomics; 2015; 16(3):257-71. PubMed ID: 25712189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.